Gapping up
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- PENG +15.6%, WBA +10.5%, ARHS +9.3% (guidance and CFO resignation), BBCP +8.8%, XERS +8.6% (guidance), ATRO +7.4% (guidance), BCRX +6.5% (guidance), DAL +6.3%, BDSX +4.7% (guidance), GMED +4%, GBX +1.6%, TSM +0.9% (Dec sales)
Other news:
- AKYA +63.2% (confirms it is to be acquired by Quanterix Corporation)
- DTIL +31.6% (Announces Complete Clinical Response in First Infant Dosed by Partner iECURE in Ongoing Phase 1/2 Clinical Trial in Ornithine Transcarbamylase (OTC) Deficiency)
- DBVT +16.7% (results from EPITOPE Phase 3 study)
- ABOS +14.7% (announces journal of prevention of alzheimer's disease publication of the company's phase 1 intercept-ad study, including target engagement, dosing regimen and safety findings)
- MRAM +14.4% (appoints new CFO)
- CEG +9.5% (confirms plans to acquire Calpine at an equity purchase price of approximately $16.4 billion)
- ZNTL +9% (announces azenosertib fast track designation and virtual corporate event to present updated data from azenosertib clinical studies)
- QTRX +8.8% (completed the acquisition of Emission pursuant to Dec 16 Share Purchase Agreement)
- CCO +7.9% (to sell its Europe-north segment to a subsidiary of Bauer Media Group for $625 mln)
- ITOS +7.4% (outlines business updates and strategic priorities for 2025)
- CVEO +7.1% (receives Civeo receives six-year contract extension from leading resource player)
- TUYA +6.3% (Hosts Successful 'Tuya Developer Day' During CES 2025, Leading Industry Change with Innovative AI Technology)
- CMPS +6% (announces the pricing of an underwritten offering of 24,014,728 American Depositary Shares and in lieu of ADS, to certain institutional investors, pre-funded warrants to purchase up to 11,044,720 ADSs)
- FVR +5.9% (REIT provides Q4 business update)
- W +4.9% (announced its decision to exit the German market, effective immediately)
- TLSI +4.6% (announces publication of pre-clinical data demonstrating improved delivery of Embospheres)
- RIGL +4.1% (R289 granted orphan drug designation by the FDA for MDS)
- RPRX +4% (announces two major steps to enhance shareholder value; raises dividend by 5%)
- ABVX +3.9% (Achieves Key Milestone in Phase 3 ABTECT Trial Enrollment)
- ZLAB +3.9% (forms strategic partnership with MediLink Therapeutics to develop a novel LRRC15 antibody-drug conjugate)
- PECO +3.2% (extends maturity of upsized revolving credit facility)
- SPHR +3% (appoints new CFO)
- APD +2.7% (issues response to Mantle Ridge; sends letter to shareholders correcting Mantle Ridge's falsehoods and misleading claims)
- LUV +2.5% (CFO to retire April 1)
- PLYM +2.5% (reports Q4 activity update)
- QBTS +2.3% (CEO Dr. Alan Baratz Addresses NVIDIA CEO Jensen Huang's Quantum Comments on CNBC's "The Exchange"; announces that fiscal year 2024 bookings will exceed $23 million, an increase of approximately 120% over fiscal year 2023 bookings)
- NVO +2.2% (Coave Therapeutics secures €32 million ($33 million) in series A financing to advance its next-generation genetic medicines)
- IPHA +2.2% (Announces Transformative Strategy to Accelerate Growth)
- TGB +1.9% (announces 2024 production results)